<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Polysaccharide-iron complex, vitamin B12, and folic acid: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Polysaccharide-iron complex, vitamin B12, and folic acid: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Polysaccharide-iron complex, vitamin B12, and folic acid: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12295" href="/d/html/12295.html" rel="external">see "Polysaccharide-iron complex, vitamin B12, and folic acid: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F10009734"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ferrex 150 Forte [OTC];</li>
<li>Folvite-Fe [DSC];</li>
<li>Hematogen Forte [DSC];</li>
<li>Hematogen Forte [OTC];</li>
<li>IFerex 150 Forte;</li>
<li>Irofol [OTC] [DSC];</li>
<li>Poly-Iron 150 Forte;</li>
<li>Trigels-F Forte</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F10009737"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Iron Preparations</li></ul></div>
<div class="block doa drugH1Div" id="F10009755"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Formulation:</b> Enteric-coated and slow-/sustained-release preparations are generally not preferred due to poor absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24215034','lexi-content-ref-22157204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24215034','lexi-content-ref-22157204'])">Ref</a></span>). <b>Route of administration:</b> IV iron replacement is preferred over oral replacement in several clinical situations (eg, lack of response to or poor tolerability of oral iron, chronic kidney disease, extensive blood loss) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26408108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26408108'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b436553f-e87b-4e50-bebe-e1eddbb5c878">Iron-deficiency anemia, prevention/treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, prevention/treatment:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Once-daily regimen:</i></b> One capsule or tablet once daily. <b>Note:</b> Available products have varying products of iron and other components in the preparation; consult specific product labeling. Some experts do not typically exceed one dose per day as higher iron doses do not necessarily improve absorption and may increase the risk of adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26494915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26494915'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Alternate-day dosing regimens (off-label): </i></b>One capsule or tablet every other day <b>or</b> one capsule or tablet on Monday, Wednesday, Friday (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26494915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26494915'])">Ref</a></span>). <b>Note:</b> Data have shown that alternate-day dosing regimens result in greater absorption of iron compared to more frequent administration; some experts prefer alternate-day dosing regimens in patients who can maintain adherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29032958','lexi-content-ref-26289639','lexi-content-ref-29032957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29032958','lexi-content-ref-26289639','lexi-content-ref-29032957'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991903"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989127"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F10009756"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F10009747"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (extremities and facial flushing)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Precordial pain</p></div>
<div class="block coi drugH1Div" id="F50711327"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to any components of the formulation; hemochromatosis; hemosiderosis.</p></div>
<div class="block war drugH1Div" id="F10009744"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anemia: Not appropriate for treatment of pernicious or aplastic anemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Avoid in patients with peptic ulcer disease, enteritis, or ulcerative colitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pernicious anemia: Folate doses &gt;0.1 mg/day may obscure pernicious anemia in that hematologic remission can occur with continuing irreversible nerve damage progression.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Oral iron formulations: Immediate release oral iron products are preferred for treatment of iron deficiency anemia; enteric coated and slow/sustained release preparations are not desired due to poor absorption (Hershko 2014; Liu 2012).</p></div>
<div class="block foc drugH1Div" id="F10009766"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferrex 150 Forte: Elemental iron 150 mg, cyanocobalamin 25 mcg, and folic acid 1 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hematogen Forte: Iron 460 mg, cyanocobalamin 10 mcg, and folic acid 1 mg with ascorbic acid 60 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #5 (tartrazine), soybean lecithin, soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IFerex 150 Forte: Elemental iron 150 mg, cyanocobalamin 25 mcg, and folic acid 1 mg [contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Poly-Iron 150 Forte: Elemental iron 150 mg, cyanocobalamin 25 mcg, and folic acid 1 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trigels-F Forte: Iron 460 mg, cyanocobalamin 10 mcg, and folic acid 1 mg with ascorbic acid 60 mg [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Folvite-Fe: Iron 90 mg, cyanocobalamin 12 mcg, and folic acid 1 mg with ascorbic acid 120 mg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #5 (tartrazine)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Irofol: Elemental iron 150 mg, cyanocobalamin 25 mcg, and folic acid 1 mg [DSC]</p></div>
<div class="block geq drugH1Div" id="F10009735"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16322836"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ferrex 150 Forte Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150-0.025-1 mg (per each): $0.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Hematogen Forte Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">460-60-0.01-1 mg (per each): $0.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (IFerex 150 Forte Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150-25-1 mg-mcg-mg (per each): $0.34</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F57032755"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered with or without food.</p></div>
<div class="block use drugH1Div" id="F10009740"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Iron deficiency anemia, prevention/treatment: </b>Prevention and treatment of iron-deficiency anemias.</p></div>
<div class="block cyt drugH1Div" id="F13299908"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F10073257"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Iron Preparations may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Preparations.  Management: Separate administration of alpha-lipoic acid from that of any iron-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral iron-containing products at lunch or dinner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Iron Preparations. Management: No action is likely necessary for the majority of patients who only use antacids intermittently or occasionally. Consider separating doses of oral iron and antacids in patients who require chronic use of both agents and monitor for reduced iron efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Iron Preparations may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron preparations under fed conditions, but coadministration with or 2 hours after an iron preparation is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefdinir: Iron Preparations may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible. Separate doses by at least 2 hours if combined. Iron-containing infant formulas do not appear alter cefdinir pharmacokinetics, but red-appearing, non-bloody stools may develop when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimercaprol: May enhance the nephrotoxic effect of Iron Preparations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Iron Preparations may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral iron. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron. Alternatively, dolutegravir and oral iron can be taken together with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entacapone: Iron Preparations may decrease the serum concentration of Entacapone.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Hydroxide Polymaltose Complex: May decrease the serum concentration of Iron Preparations. Specifically, the absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) ferric hydroxide polymaltose complex with other oral iron preparations. Therapy with oral iron preparations should begin 1 week after the last dose of IV ferric hydroxide polymaltose complex.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: Folic Acid may enhance the adverse/toxic effect of Fluorouracil Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Folic Acid may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Green Tea: May decrease the serum concentration of Folic Acid.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa: Iron Preparations may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Iron Preparations may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Iron Preparations may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron preparations and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron preparations or levothyroxine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methyldopa: Iron Preparations may decrease the serum concentration of Methyldopa.  Management: Consider separating doses of methyldopa and orally administered iron preparation by 2 or more hours. Monitor for decreased efficacy of methyldopa if an oral iron preparation is initiated/dose increase, or increased efficacy if discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pafolacianine: Folic Acid may diminish the diagnostic effect of Pafolacianine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: Folic Acid may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Iron Preparations may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral iron preparation as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Iron Preparations. Management: Give oral iron products at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: Folic Acid may decrease the serum concentration of Primidone. Additionally, folic acid may decrease concentrations of active metabolites of primidone (e.g., phenobarbital). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyrimethamine: Folic Acid may diminish the therapeutic effect of Pyrimethamine.  Management: Folic acid doses greater than 2.5 mg per day should be avoided due to the potential for sulfadoxine/pyrimethamine treatment failure. Consider limiting folic acid use to no more than 0.4 mg per day for women of child-bearing age.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Iron Preparations may decrease the serum concentration of Quinolones.  Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, oflox-, peflox, or nalidixic acid) oral iron.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir.  Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltitrexed: Folic Acid may diminish the therapeutic effect of Raltitrexed. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfadoxine: Folic Acid may diminish the therapeutic effect of Sulfadoxine.  Management: Folic acid doses greater than 2.5 mg per day should be avoided due to the potential for sulfadoxine/pyrimethamine treatment failure. Consider limiting folic acid use to no more than 0.4 mg per day for women of child-bearing age.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SulfaSALAzine: May decrease the serum concentration of Folic Acid.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May decrease the absorption of Iron Preparations. Iron Preparations may decrease the serum concentration of Tetracyclines. Management: Avoid this combination if possible. Administer oral iron preparations at least 2 hours before, or 4 hours after, the dose of the oral tetracycline derivative. Monitor for decreased therapeutic effect of oral tetracycline derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F10009741"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Refer to individual monographs</p></div>
<div class="block brc drugH1Div" id="F10009743"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Refer to individual monographs</p></div>
<div class="block dic drugH1Div" id="F10009757"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Dietary sources of iron include beans, cereal (enriched), clams, beef, lentils, liver, oysters, shrimp, and turkey. Foods that enhance dietary absorption of iron include broccoli, grapefruit, orange juice, peppers and strawberries. Foods that decrease dietary absorption of iron include coffee, dairy products, soy products, spinach, and tea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary reference intake (IOM 2001):</b></p>
<p style="text-indent:-2em;margin-left:4em;">0 to 6 months of age: Adequate intake: 0.27 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">7 to 12 months of age: RDA: 11 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years of age: RDA: 7 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years of age: RDA: 10 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 13 years of age: RDA: 8 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">14 to 18 years of age: RDA:</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 11 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 15 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnant patients: 27 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Lactating patients: 10 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">19 to 50 years of age: RDA:</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 8 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 18 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnant patients: 27 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Lactating patients: 9 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">≥50 years of age: RDA: 8 mg elemental iron/day.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58207748"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Femolbin q plus | Ferose | Ferri q | Ferriforce | Ferrinough f | Ferripol | Ferripol m | Ferritap F | Ferritop f | Feva gold | Gogai q | Hegatin Gold | Hemo Q Plus | Hemodeun | Hemodipine Plus | Hemodoctor f | Hemoformin | Hemoformin q | Hemogenic forte | Hemolbin Q | Hemolock a | Hemomom plus | Hemopol Plus | Hemoqueen Gold | Hemoqueentap | Hemostin | Hepomin | Hepomin f | Sk hemoone</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ferrex 150 forte | Niferex forte</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fer max</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ferich Forte | Your iron</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26408108">
<a name="26408108"></a>Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. <i>Am J Hematol</i>. 2016;91(1):31-38. doi:10.1002/ajh.24201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-vitamin-b12-and-folic-acid-drug-information/abstract-text/26408108/pubmed" id="26408108" target="_blank">26408108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29032958">
<a name="29032958"></a>Auerbach M, Schrier S. Treatment of iron deficiency is getting trendy. <i>Lancet Haematol</i>. 2017;4(11):e500-e501. doi:10.1016/S2352-3026(17)30194-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-vitamin-b12-and-folic-acid-drug-information/abstract-text/29032958/pubmed" id="29032958" target="_blank">29032958</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  BiferaRx (Polysaccharide-Iron Complex, Vitamin B12, and Folic Acid) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; received May 2022.</div>
</li>
<li>
<div class="reference">
                  Hematogen Forte (polysaccharide-iron complex, vitamin B<sub>12</sub>, and folic acid) [prescribing information]. Cincinnati, OH: Nnodum Pharmaceuticals; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24215034">
<a name="24215034"></a>Hershko C and Camaschella C. How I treat unexplained refractory iron deficiency anemia. <i>Blood.</i> 2014;123(3):326-333. doi: 10.1182/blood-2013-10-512624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-vitamin-b12-and-folic-acid-drug-information/abstract-text/24215034/pubmed" id="24215034" target="_blank">24215034</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Iferex 150 Forte (polysaccharide-iron complex, vitamin B<sub>12</sub>, and folic acid) [prescribing information]. Cincinnati, OH: Nnodum Pharmaceuticals; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine), <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>, Washington, DC: National Academy Press, 2001.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22157204">
<a name="22157204"></a>Liu K and Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. <i>Eur J Gastroenterol Hepatol</i>. 2012;24(2):109-116. doi: 10.1097/MEG.0b013e32834f3140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-vitamin-b12-and-folic-acid-drug-information/abstract-text/22157204/pubmed" id="22157204" target="_blank">22157204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26289639">
<a name="26289639"></a>Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. <i>Blood</i>. 2015;126(17):1981-1989. doi:10.1182/blood-2015-05-642223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-vitamin-b12-and-folic-acid-drug-information/abstract-text/26289639/pubmed" id="26289639" target="_blank">26289639</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Myferon 150 Forte (polysaccharide-iron complex, vitamin B<sub>12</sub>, and folic acid) [prescribing information]. Richmond, IN: M.E. Pharmaceuticals Inc; February 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9563847">
<a name="9563847"></a>“Recommendations to Prevent and Control Iron Deficiency in the United States. Centers for Disease Control and Prevention,” <i>MMWR Recomm Rep</i>, 1998, 47(RR-3):1-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-vitamin-b12-and-folic-acid-drug-information/abstract-text/9563847/pubmed" id="9563847" target="_blank">9563847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26494915">
<a name="26494915"></a>Schrier SL. So you know how to treat iron deficiency anemia. <i>Blood</i>. 2015;126(17):1971. doi:10.1182/blood-2015-09-666511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-vitamin-b12-and-folic-acid-drug-information/abstract-text/26494915/pubmed" id="26494915" target="_blank">26494915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schrier.1">
<a name="Schrier.1"></a>Schrier SL, Auerbach M. Treatment of iron deficiency anemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 25, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29032957">
<a name="29032957"></a>Stoffel NU, Cercamondi CI, Brittenham G. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. <i>Lancet Haematol</i>. 2017;4(11):e524-e533. doi: 10.1016/S2352-3026(17)30182-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-vitamin-b12-and-folic-acid-drug-information/abstract-text/29032957/pubmed" id="29032957" target="_blank">29032957</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Trigels-F Forte (polysaccharide-iron complex, vitamin B<sub>12</sub>, and folic acid) [prescribing information]. Alpharetta, GA: Trigen Laboratories LLC; November 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9908 Version 207.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
